Structure Therapeutics Inc. (GPCR) Stock: Price, Forecast & Analyst Target
Structure Therapeutics Inc. (GPCR) — MoonshotScore 56/100 (Fair band), calculated Nov 18, 2026. Price $17.12 (-1.38%), as of the Nov 19, 2026 trading session; market cap $1.23B.
Educational signal · not a buy or sell recommendation · How to read this
Structure Therapeutics Inc. · GPCR · NASDAQ
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel oral therapeutics for chronic diseases, leveraging its expertise in G-protein-coupled receptors (GPCRs).
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Structure Therapeutics (GPCR)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fortress balance sheet, but stalling growth and a full valuation, and the price trend has turned against it. Business Quality: Average; Financial Safety: Fortress; Valuation: Full; Growth Durability: Shrinking; Momentum: Slipping.
- EPS beat 1 of the last 4 reports
- Altman Z 5.06 · Piotroski F 2
- ROE -21.2% · ROA -22.0% · current ratio 11.91 · earnings yield -21.7% · free-cash-flow yield -25.9%
Holding back: soft growth, weak price trend
Helping: balance-sheet strength
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 54 | Fair | |
| 55 | Fair | |
| 54 | Fair | |
| 54 | Fair | |
| 56 | Fair | |
| 56 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $17.12 | |
| Change on the day | -1.38% | |
| 52-week range | $17.12 – $94.90 | |
| Market capitalisation | $1.23B | — |
| Shares traded on the day | 586.2K |
Price & events
Other perspectives
Council score for Structure Therapeutics (GPCR): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Structure Therapeutics (GPCR), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Structure Therapeutics Inc. (GPCR) is listed on NASDAQ. It employs 281 people and is led by Raymond C. Stevens. The market values it at $1.23B.
What do the latest results show for Structure Therapeutics (GPCR)?
Short answer · as of
Against analyst estimates the company has EPS beat 1 of the last 4 reports.
What are the financial strengths and risks for Structure Therapeutics (GPCR)?
Short answer · as of
The MoonshotScore pillars rate balance-sheet strength as strengths. What is holding it back is soft growth, weak price trend. The distress and quality screens read Altman Z 5.06 · Piotroski F 2. Trailing ratios: ROE -21.2% · ROA -22.0% · current ratio 11.91 · earnings yield -21.7% · free-cash-flow yield -25.9%.
Data-derived red flags
- Negative return on equity (-21.2%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 1 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at Structure Therapeutics (GPCR)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $38.46M · EPS -2.13 · 7 analysts. Current published price targets run low $70.00 · high $111.00 · consensus $90.50 · median $90.50 against a quoted price of $17.12 (as of Nov 19, 2026).
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for GPCR.
Checked against the records this page reads, on the dates shown above.
How does Structure Therapeutics compare with its peers?
Short answer
Structure Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $61.99 Nov 18, 2026 | $1.79B | 98 5-pillar Nov 18, 2026 | |
| $14.10 Nov 18, 2026 | $1.54B | 97 5-pillar Nov 18, 2026 | |
| $14.89 Nov 19, 2026 | $2.00B | 97 5-pillar Nov 18, 2026 | |
| $18.40 Nov 18, 2026 | $1.31B | 96 5-pillar Nov 18, 2026 | |
| $33.11 Nov 18, 2026 | $1.94B | 96 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $47.40 Nov 19, 2026 | $1.41B | 76 5-pillar Nov 18, 2026 | |
| $40.04 Nov 19, 2026 | $1.30B | 69 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $18.52 Nov 19, 2026 | $1.14B | 66 5-pillar Nov 18, 2026 | |
| $30.78 Nov 19, 2026 | $1.03B | 64 5-pillar Nov 18, 2026 | |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 | |
| Structure Therapeutics (GPCR) — this page | $17.12 | $1.23B | 56 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $70.00 – $111.00
- Consensus target
- $90.50
- Median target
- $90.50
- Revenue estimate
- $38.46M
- EPS estimate
- $-2.13
Consensus record · Captured .
Measured against a quoted price of $17.12 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 21, 2026
- Transactions
- 45
- Identified insiders
- 10
- Purchases
- 0
- Sales
- 14
- Other transactions
- 31
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held GPCR in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported GPCR in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Structure Therapeutics (GPCR)?
- Structure Therapeutics (GPCR) Posts Wider Losses, Is The Discount Too Deep?
- Morgan Stanley Adjusts Price Target on Structure Therapeutics
- Morgan Stanley Adjusts Price Target on Structure Therapeutics to $117 From $126, Keeps Outperform Rating
- Structure Therapeutics Announces Collaboration with Unlearn to Apply AI-Generated Digital Twins in Obesity Research
Common Questions About GPCR
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for GPCR?
GPCR carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is GPCR a good stock to buy?
Stock Expert AI does not rate GPCR buy, sell or hold. Structure Therapeutics Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the GPCR stock price today?
The last price recorded for Structure Therapeutics Inc. (GPCR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the GPCR price target?
The analyst consensus price target for Structure Therapeutics Inc. (GPCR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the key factors to evaluate for GPCR?
Structure Therapeutics Inc. (GPCR) holds a MoonshotScore in the moderate range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Its pipeline includes three distinct oral small molecule therapeutics, demonstrating a diversified approach to addressing chronic diseases. Not financial advice.
How frequently does GPCR data refresh on this page?
GPCR's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven GPCR's recent stock price performance?
Structure Therapeutics Inc. (GPCR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline of oral small molecule GPCR-targeted therapeutics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GPCR overvalued or undervalued right now?
Structure Therapeutics Inc. (GPCR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research GPCR before investing?
Before investing in Structure Therapeutics Inc. (GPCR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 20 figures on this page — 10 from Financial Modeling Prep (FMP), 9 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
ETFs that hold GPCR
Funds in our ETF coverage that list GPCR among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| WisdomTree BioRevolution Fund (WDNA) | 2.69% |